Docoh
Loading...

FMTX Forma Therapeutics

APP
Utility
Fused Pyrrolines Which Act As Ubiquitin-specific Protease 30 (USP30) Inhibitors
18 Nov 21
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 4 Oct 19
APP
Utility
Inhibiting Ubiquitin Specific Peptidase 9X
11 Nov 21
This disclosure provides methods of treating cancer with an inhibitor of ubiquitin specific peptidase 9X alone or in combination with an immune checkpoint pathway inhibitor.
Maureen LYNES, Weiping WANG, Bruce FOLLOWS, Katherine J. KAYSER-BRICKER, Adam Charles TALBOT, Scot MENTE, Tatiana SHELEKHIN, Anna ERICSSON
Filed: 19 Sep 19
GRANT
Utility
Purinones as ubiquitin-specific protease 1 inhibitors
2 Nov 21
Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin A. Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
Filed: 14 Aug 19
APP
Utility
Activating Pyruvate Kinase R
7 Oct 21
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
Filed: 18 Jun 21
GRANT
Utility
Tetrahydroquinoline compositions as BET bromodomain inhibitors
7 Sep 21
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
Filed: 28 Jan 20
APP
Utility
Salts of (S)-(5-CYCLOBUTOXY-2-METHYL-6-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)-3,4-DIHYDROQUINOLIN-1(2H)-YL)(CYCLOPROPYL)METHANONE and Solid Forms Thereof
26 Aug 21
The present disclosure reports salts of (S)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)(cyclopropyl)methanone, solid forms thereof, and methods of making and using the same.
George P. Luke
Filed: 28 Jun 19
APP
Utility
Treatment of Glioblastoma with Fasn Inhibitors
19 Aug 21
The present disclosure relates to methods of treating glioblastoma by administering to a patient in need thereof a FASN inhibitor.
Wei LU, Matthew W. MARTIN, Erik WILKER, Howard FINE
Filed: 25 Oct 18
APP
Utility
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
12 Aug 21
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Susan ASHWELL, Blythe THOMSON, Patrick F. KELLY, Alan COLLIS, Jeff DAVIS, Duncan WALKER, Wei LU
Filed: 28 Apr 21
APP
Utility
Pyrrolopyrrole Compositions As Pyruvate Kinase (PKR) Activators
12 Aug 21
The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds.
Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
Filed: 23 Apr 21
GRANT
Utility
Benzopiperazine compositions as BET bromodomain inhibitors
10 Aug 21
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
Filed: 12 May 20
GRANT
Utility
Activating pyruvate kinase R
27 Jul 21
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
Filed: 1 May 20
APP
Utility
Activating Pyruvate Kinase R and Mutants Thereof
22 Jul 21
The disclosure provides chemical compounds useful as activators of PKR.
David R. Lancia, JR., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
Filed: 6 Apr 21
APP
Utility
Novel Compounds and Compositions for Inhibition of Fasn
15 Jul 21
Kenneth W. Bair, David R. Lancia, JR., Hongbin LI, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
Filed: 26 Feb 21
APP
Utility
Fused Bicyclic Compounds Useful As Ubiquitin-specific Peptidase 30 Inhibitors
1 Jul 21
Matthew W. MARTIN, Alexandre Joseph BUCKMELTER
Filed: 16 May 19
APP
Utility
Inhibiting Mutant IDH-1
1 Jul 21
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 16 May 19
APP
Utility
Solid Forms of ((S)-5-((1-(6-CHLORO-2-OXO-1,2-DIHYDROQUINOLIN-3-YL)ETHYL)AMINO)-1-METHYL-6-OXO-1,6-DIHYDROPYRIDINE-2-CARBONITRILE
17 Jun 21
The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
George P. Luke, Pratik Sheth
Filed: 24 Feb 21
GRANT
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
25 May 21
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Filed: 4 Jun 19
GRANT
Utility
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
25 May 21
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 30 Jul 19
GRANT
Utility
Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
25 May 21
Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
Filed: 20 Mar 18
GRANT
Utility
Activating pyruvate kinase R and mutants thereof
11 May 21
The disclosure provides chemical compounds useful as activators of PKR.
David R. Lancia, Jr., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
Filed: 19 Sep 19
Patents are sorted by USPTO publication date, most recent first